These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11788050)

  • 1. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
    Dickey CA; Morgan DG; Kudchodkar S; Weiner DB; Bai Y; Cao C; Gordon MN; Ugen KE
    DNA Cell Biol; 2001 Nov; 20(11):723-9. PubMed ID: 11788050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine.
    Li SB; Wang HQ; Lin X; Xu J; Xie Y; Yuan QF; Yao ZB
    Chin Med J (Engl); 2005 Apr; 118(8):660-4. PubMed ID: 15899121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory.
    Arendash GW; Gordon MN; Diamond DM; Austin LA; Hatcher JM; Jantzen P; DiCarlo G; Wilcock D; Morgan D
    DNA Cell Biol; 2001 Nov; 20(11):737-44. PubMed ID: 11788052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
    Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA
    Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology.
    Vehmas AK; Borchelt DR; Price DL; McCarthy D; Wills-Karp M; Peper MJ; Rudow G; Luyinbazi J; Siew LT; Troncoso JC
    DNA Cell Biol; 2001 Nov; 20(11):713-21. PubMed ID: 11788049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
    Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
    Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives].
    Karkos J
    Fortschr Neurol Psychiatr; 2004 Apr; 72(4):204-19. PubMed ID: 15095177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice.
    Li Q; Cao C; Chackerian B; Schiller J; Gordon M; Ugen KE; Morgan D
    BMC Neurosci; 2004 Jun; 5():21. PubMed ID: 15186505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid β 3-10 DNA vaccination suggests a potential new treatment for Alzheimer's disease in BALB/c mice.
    Xing XN; Zhang WG; Sha S; Li Y; Guo R; Wang C; Cao YP
    Chin Med J (Engl); 2011 Sep; 124(17):2636-41. PubMed ID: 22040416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
    Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
    J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid-β peptide in mice through regulatory T cell-mediated inhibition.
    Toly-Ndour C; Lui G; Nunes MM; Bruley-Rosset M; Aucouturier P; Dorothée G
    J Immunol; 2011 Nov; 187(9):4492-500. PubMed ID: 21949026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
    Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
    J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.
    Seabrook TJ; Thomas K; Jiang L; Bloom J; Spooner E; Maier M; Bitan G; Lemere CA
    Neurobiol Aging; 2007 Jun; 28(6):813-23. PubMed ID: 16725229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats.
    Subramanian S; Divya Shree AN
    Neurosci Lett; 2008 May; 436(2):219-22. PubMed ID: 18394801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.